Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT03936153 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG: abexinostat

Sponsor

Xynomic Pharmaceuticals, Inc.